Moreover, NT-proBNP is considered not to be an optimal surrogate target for the therapy in T2DM with obesity, chronic kidney disease, and HFpEF due to its high serum variability, low diabetes risk and uncertainty in connection with echocardiographic parameters [40]. This evidence concerns the gene NPPB and Obesity.